Latest from MD Anderson

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses emerging treatment strategies in mantle cell lymphoma.
David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the design of the InnovaTV 201 trial in cervical cancer.
Funda Meric-Bernstam, MD, chair, Department of Investigational Cancer Therapeutics, medical director, Institute for Personalized Cancer Therapy, professor of medicine, The University of Texas MD Anderson Cancer Center, discussed preliminary data with a novel combination in the treatment of patients with renal cell carcinoma.
The University of Texas MD Anderson Cancer Center named David Jaffray, PhD, as its first-ever chief technology and digital officer.
Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the biology of right- versus left-sided colorectal cancer.
David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of tisotumab vedotin (HuMax-TF-ADC) in patients with cervical cancer.
Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses the importance of early genomic testing in patients with colorectal cancer.
Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the significance of tumor sidedness in colorectal cancer.
Publication Bottom Border
Border Publication
x